Clinical Trial

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-13
notable Enrollment reduced: 186 -> 37 participants 2026-08-13
Trial Details
NCT Number NCT06313593
Lead Sponsor Incyte Corporation
Conditions Myeloproliferative Neoplasms
Enrollment 37 participants
Start Date 2024-08-08
Primary Completion 2028-10-09 (estimated)
Study Completion 2028-10-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-12